ASH 2020 | Phase III trial of intensification and consolidation therapy in newly diagnosed myeloma

Pieter Sonneveld, MD, PhD, Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands, discusses the long-term follow-up results of the Phase III EMN02/HO95 study (NCT01208766) of intensification and consolidation therapy in newly diagnosed multiple myeloma (NDMM). The study employed two randomization phases: over 1200 patients were initially randomized to either bortezomib-melphalan-prednisone (VMP) intensification therapy or upfront autologous hematopoietic stem cell transplantation (ASCT), followed by randomization to consolidation or no consolidation. 878 patients were randomized to bortezomib-lenalidomide-dexamethasone (VRD) consolidation versus no consolidation. The results showed that consolidation treatment with VRD followed by continuous lenalidomide maintenance improves progression-free survival (PFS) and quality of response in NDMM as compared to maintenance alone. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.